Reading TCRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRX free→Reading TCRX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track TCRX free→QuarterlyIQ Insights · TCRX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 6, 2026, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 31, 2026, Leiden Dworak notified TScan Therapeutics, Inc. (the “Company”) of his decision to resign as Vice President of Finance of the Company and principal accounting officer effective April 10, 2026. There were no disagreements between the Company and Mr. Dworak relating to the Company’s operations, policies or practices. In connection…
Results of Operations and Financial Condition. On March 4, 2026, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities E…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On November 25, 2025, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”), upon the recommendation of the Compensation Committee, approved a retention program designed to retain the employees required to support the Company, including a key employee retention program (the “Retention Program”) that provides for cash awar…
Results of Operations and Financial Condition. On November 12, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the third quarter September 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 193…
Regulation FD Disclosure. On November 3, 2025, the Company issued a press release announcing its alignment with the Food & Drug Administration on the pivotal study design for TSC-101, the Company’s strategic decision to prioritize clinical development of its heme program, while pausing further enrollment in its solid tumor Phase 1 trial and focusing preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity, as well as a workforce reduction of approximate…
Other Events. On November 3, 2025, the Company announced the following updates: Hematologic Malignancies Program • In October 2025, the Company met with the FDA regarding a pivotal trial design for TSC-101, which is designed to treat residual disease and prevent relapse in patients with AML or MDS undergoing allogeneic hematopoietic cell transplantation (HCT) with reduced intensity conditioning (RIC). The interaction was productive and the FDA has agreed to a study design that mirrors the cur…
Costs Associated with Exit or Disposal Activities. On November 3, 2025, TScan Therapeutics, Inc. (the “Company”) initiated a prioritization strategy by which the Company will prioritize the clinical development of its heme program, pause further enrollment in its solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. Pursuant to such strategy, the Company also implemented a workforce reduction of approximately 30%…
Appointment of Certain Officers. On August 14, 2025, the Board of Directors (the “Board”) of TScan Therapeutics, Inc. (the “Company”) appointed Leiden Dworak, Vice President, Finance of the Company, as the Company’s Principal Accounting Officer, effective August 14, 2025. Upon the effectiveness of such appointment, Jason A. Amello ceased to serve as the Company’s Principal Accounting Officer, but Mr. Amello continues to serve as the Company’s Chief Financial Officer and Principal Financial Of…
Results of Operations and Financial Condition. On August 12, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the second quarter June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as…
Results of Operations and Financial Condition. On May 6, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the first quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Results of Operations and Financial Condition. On March 5, 2025, TScan Therapeutics, Inc. issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall neither be deemed “filed” for purposes of Section 18 of the Securities E…
Importance-ranked changes since the prior daily snapshot.
Valuation label changed from 'full' to 'fair'.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.